Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 16, 2009

Premium

Title: RNA Interference-Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 7,517,864

Filed: Dec. 9, 2005

Lead Inventor: Chandra Vargeese, Sirna Therapeutics (Merck)

The invention, the patent's abstract states, "relates to compounds, compositions, and methods useful for modulating VEGF and/or VEGFR gene expression using short interfering nucleic acid molecules … [as well as] compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of VEGF and/or VEGFR gene expression and/or activity by RNA interference using small nucleic acid molecules."

The patent specifically claims small nucleic acid molecules … and methods "used to modulate the expression of VEGF and/or VEGFR genes … [and] methods of treating diseases and conditions associated with VEGF and/or VEGFR gene expression, such as ocular diseases and conditions, including age related macular degeneration (AMD) and diabetic retinopathy, as well as providing dosing regimens and treatment protocols."


Title: RNAi Modulation of RSV and Therapeutic Uses Thereof

Number:
7,517,865

Filed: April 26, 2006

Inventor:
Rachel Meyers, Alnylam Pharmaceuticals

The invention, the patent's abstract states, "is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of [interfering] RNA agents, as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human."

The abstract notes that "these findings can be applied to other respiratory viruses."


Title: miRNA-Processing Inhibitor Efficacy Assays and Substances

Number: 20090092980

Filed:
July 18, 2008

Lead Inventor:
Christoph Arenz, Humboldt University

"The invention relates to assays for assessing [microRNA] maturation effector efficacy and to substances useful for influencing, particularly for inhibiting, maturation of miRNA," according to the patent application's abstract. The invention comprises an "assay of miRNA-processing inhibitor efficacy [by] …providing a target miRNA precursor; providing a potential inhibitor of one or more processing steps of the target miRNA precursor; bringing together of the target miRNA precursor and the potential inhibitor under miRNA maturation conditions; and determining inhibition efficiency. The assay … allows for a very fast and easy assessment of the efficacy of a potential inhibitor in inhibiting processing of a miRNA precursor into miRNA."

[ pagebreak ]

Title:
Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts

Number: 20090092988

Filed: Oct. 6, 2008

Lead Inventor:
Jacob Schwartz, University of Texas Southwestern Medical Center

The invention, the patent application's abstract states, relates to the selective modulating of gene expression in the genome of a mammalian cell by "determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene."



Title:
Transducible Delivery of siRNA by dsRNA-Binding Domain Fusions to PTD/CPPS

Number:
20090093026

Filed: Feb. 9, 2007 PCT Filed: Feb. 9, 2007

Lead Inventor: Steven Dowdy, University of California, San Diego

The invention, the patent application's abstract, states comprises "fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject. The fusion constructs include a protein-transduction domain and a nucleic acid-binding domain, or a protein-transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid." The invention also comprises "methods of treating disease and disorders such as cell proliferative disorders."


Title: Transducible Delivery of Nucleic Acids by Reversible Phosphotriester Charge Neutralization Protecting Groups

Number: 20090093425

Filed: July 11, 2007

Lead Inventor: Steven Dowdy, University of California, San Diego

According to the patent application's abstract, the invention comprises "nucleic acid constructs modified to have a reduced net anionic charge. In some aspects, the constructs comprise phosphodiester and/or phosphothioate protecting groups."



Title:
RNAi Modulation of SCAP and Therapeutic Uses Thereof

Number: 20090093426

Filed: Sept, 18, 2007

Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a SCAP gene comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell."

[ pagebreak ]

Title: RNA Interference-Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid

Number: 20090093431

Filed: July 16, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220, NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2," the abstract adds.


Title: Tumor Inhibition by Modulating Sprouty Expression of Activity

Number: 20090093432

Filed: July 24, 2008

Lead Inventor: Justin McCormick, Michigan State University

The patent application, its abstract states, claims "methods … for identifying compounds that decrease the expression or activity of an over-expressed Sprouty protein in certain cancers. … Also provided are therapeutic formulations and pharmaceutical formulations for treating cancers characterized by over-expression of a Sprouty protein."


Title: Use of EIF-5A1 siRNA to Protect Islet Cells from Apoptosis and to Preserve Their Functionality

Number: 20090093434

Filed: Aug. 20, 2008

Lead Inventor:
John Thompson, Senesco Technologies

The invention, the patent application's abstract states, "relates to methods for improving the viability, recovery, and functionality of islets that are separated from a donor organ for subsequent transplantation, and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability and functionality of islets."

[ pagebreak ]


Title:
RNA Interference-Mediated Inhibition of GRB2-Associated Binding Protein Gene Expression Using Short Interfering Nucleic Acid

Number: 20090093435

Filed: Sept 2, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating associated binding protein gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of associated binding protein gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of GAB2 genes. The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease, inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions," the abstract adds.


Title: RNA Interference-Mediated Inhibition of Vascular Cell Adhesion Molecule Gene Expression Using Short Interfering Nucleic Acid

Number:
20090093436

Filed: Sept 2, 2008

Lead Inventor:
James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion molecule gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of vascular cell adhesion molecule genes, such as vascular cell adhesion molecule-1," the abstract adds.


Title: RNA Interference-Mediated Inhibition of Checkpoint Kinase-1 Gene Expression Using Short Interfering Nucleic Acid

Number: 20090093437

Filed: Sept 2, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating checkpoint kinase gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of checkpoint kinase gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of checkpoint kinase genes," the abstract adds.

[ pagebreak ]

Title: RNA Interference-Mediated Inhibition of XIAP Gene Expression Using Short Interfering Nucleic Acid

Number: 20090093438

Filed:
Sept 2, 2008

Lead Inventor:
James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of XIAP genes," the abstract adds.


Title: RNA Interference-Mediated Inhibition of Chromosome Translocation Gene Expression Using Short Interfering Nucleic Acid

Number:
20090093439

Filed:
Sept 2, 2008

Lead Inventor:
James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating chromosomal translocation gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of chromosomal translocation gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of BCR-ABL, ERG, EWS-ERG, TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, and/or AML1-ETO fusion genes," the abstract adds.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.